ArticleGastroenterology and hepatology from bed to bench2017
Measuring levels of osteopontin as potential biomarker for hepatocellular carcinoma in Syrian patients.
Article in Gastroenterology and hepatology from bed to bench, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.
- A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma.Annals of medicine · 2023Pooled it
- Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.The Cochrane database of systematic reviews · 2021Pooled it
- Osteopontin as a biomarker for COVID-19 severity and multisystem inflammatory syndrome in children: A pilot study.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- The Most Promising Biomarkers of Allogeneic Kidney Transplant Rejection.Journal of immunology research · 2022Review
- Clinical and Experimental Evaluation of Diagnostic Significance of Alpha-Fetoprotein and Osteopontin at the Early Stage of Hepatocellular Cancer.Bulletin of experimental biology and medicine · 2021Article
- The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma.Cancer medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aims to evaluate plasma osteopontin (OPN) levels as a potential biomarker for hepatocellular carcinoma (HCC).
backgroundOsteopontin (OPN) is a secreted glycoprotein that is associated with tumorigenesis and metastasis.
methodsWe measured plasma levels of OPN in 26 HCC patients, 27 patients with chronic liver diseases (CLD), and 15 healthy control individuals using a standardized ELISA kit.
resultsThe mean plasma OPN level was significantly higher in the HCC group than the CLD group or the normal control group (p-value =0.001/<0.0001). Plasma OPN levels were significantly higher in patients with a tumor size >5 cm in diameter than those with tumors ≤5 cm (p=0.02). OPN levels in the HCC group were not significantly affected by advancing degree of Child-Pugh class. Diagnostic sensitivity and specificity of OPN for HCC were 61% and 82%, respectively (cut-off value: 118.69ng/mL). The area under the ROC curve (AUC) value for OPN was 0.784. However, the AUC value was 0.844 for AFP.
conclusionThe plasma levels of OPN show low diagnostic accuracy for HCC compared to AFP. However, OPN may have a complementary role in diagnosing HCC in patients with non-diagnostic levels of AFP.
Indexed as
Identifiers
28702132PMC5495895W2614887788What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.